These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 13130473

  • 1. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus.
    Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J.
    Arthritis Rheum; 2003 Sep; 48(9):2533-40. PubMed ID: 13130473
    [Abstract] [Full Text] [Related]

  • 2. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA, El-Gendi HI, Ahmed HH.
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [Abstract] [Full Text] [Related]

  • 3. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.
    Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulou E, Kortsaris A, Hatseras D.
    Eur Cytokine Netw; 2004 Feb; 15(3):231-9. PubMed ID: 15542448
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
    Sabry AA, Elbasyouni SR, Kalil AM, Abdel-Rahim M, Mohsen T, Sleem A.
    Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
    [Abstract] [Full Text] [Related]

  • 8. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schönlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications.
    Gattorno M, Picco P, Barbano G, Stalla F, Sormani MP, Buoncompagni A, Gusmano R, Borrone C, Pistoia V.
    J Rheumatol; 1998 Feb; 25(2):361-5. PubMed ID: 9489835
    [Abstract] [Full Text] [Related]

  • 9. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
    de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfá E.
    Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
    [Abstract] [Full Text] [Related]

  • 10. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, Cervera R, Ballesta A, Ingelmo M.
    Anticancer Res; 2001 Nov; 21(4B):3053-9. PubMed ID: 11712810
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease.
    Safranow K, Dziedziejko V, Rzeuski R, Czyzycka E, Wojtarowicz A, Bińczak-Kuleta A, Jakubowska K, Olszewska M, Ciechanowicz A, Kornacewicz-Jach Z, Machaliński B, Pawlik A, Chlubek D.
    Tissue Antigens; 2009 Nov; 74(5):386-92. PubMed ID: 19845893
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.
    Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnowski K, Robak T.
    Arch Immunol Ther Exp (Warsz); 1998 Nov; 46(6):375-80. PubMed ID: 9883317
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical value of soluble tumor necrosis factor-alpha receptors in patients with systemic lupus erythematosus].
    Krichevskaia OA, Kliukvina NG, Aleksandrova EN, Samsonov MIu, Nasonov EL.
    Klin Med (Mosk); 2004 Nov; 82(10):51-5. PubMed ID: 15584602
    [Abstract] [Full Text] [Related]

  • 17. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease.
    Turan B, Pfister K, Diener PA, Hell M, Möller B, Boyvat A, Ergin S, Villiger PM.
    Scand J Rheumatol; 2008 Nov; 37(2):135-41. PubMed ID: 18415772
    [Abstract] [Full Text] [Related]

  • 18. CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Patschan S, Dolff S, Kribben A, Dürig J, Patschan D, Wilde B, Specker C, Philipp T, Witzke O.
    Clin Exp Immunol; 2006 Aug; 145(2):235-42. PubMed ID: 16879242
    [Abstract] [Full Text] [Related]

  • 19. Serum soluble interleukin-2 receptor alpha in systemic lupus erythematosus.
    El-Shafey EM, El-Nagar GF, El-Bendary AS, Sabry AA, Selim AG.
    Iran J Kidney Dis; 2008 Apr; 2(2):80-5. PubMed ID: 19377213
    [Abstract] [Full Text] [Related]

  • 20. Changes in lipid profile between flare and remission of patients with systemic lupus erythematosus: a prospective study.
    Urquizu-Padilla M, Balada E, Chacon P, Pérez EH, Vilardell-Tarrés M, Ordi-Ros J.
    J Rheumatol; 2009 Aug; 36(8):1639-45. PubMed ID: 19531751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.